Ryohei Katayama, PhD - Japanese Foundation for Cancer Research - Senior Staff Scientist

Ryohei Katayama

PhD

Japanese Foundation for Cancer Research

Senior Staff Scientist

Tokyo | Japan

ORCID logohttps://orcid.org/0000-0001-7394-895X

Ryohei Katayama, PhD - Japanese Foundation for Cancer Research - Senior Staff Scientist

Ryohei Katayama

PhD

Introduction

Primary Affiliation: Japanese Foundation for Cancer Research - Tokyo , Japan

Education

Mar 2006
The University of Tokyo
Ph.D.
Pharmaceutical Science

Experience

Oct 2015 - Sep 2017
Japanese Foundation for Cancer Research
Senior Staff Scientist
The Cancer Chemotherapy Center
Jul 2012 - Sep 2015
Japanese Foundation for Cancer Research
Staff Scientist
Cancer Chemotherapy Center
Mar 2010 - Jul 2012
Massachusetts General Hospital Cancer Center
PostDoc
Oct 2017
Japanese Foundation For Cancer Research
Chief
Div. of Ecperimental Cehmotherapy, Cancer Chemotherapy Center

Publications

38Publications

2349Reads

-Profile Views

197PubMed Central Citations

A safety study of newly generated anti-podoplanin-neutralizing antibody in cynomolgus monkey ().

Oncotarget 2018 Sep 7;9(70):33322-33336. Epub 2018 Sep 7.

The Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, Tokyo, Japan.

View Article

Download full-text PDF

Source
http://www.oncotarget.com/fulltext/26055
Publisher Site
http://dx.doi.org/10.18632/oncotarget.26055DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6161800PMC
September 2018
6 Reads
6.360 Impact Factor

Identification of Mutation Accumulation as Resistance Mechanism Emerging in First-Line Osimertinib Treatment.

J Thorac Oncol 2018 07 24;13(7):915-925. Epub 2018 Apr 24.

Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, Tokyo, Japan. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2018.04.005DOI Listing
July 2018
6 Reads
5.282 Impact Factor

3D culture system containing gellan gum restores oncogene dependence in ROS1 rearrangements non-small cell lung cancer.

Biochem Biophys Res Commun 2018 06 10;501(2):527-533. Epub 2018 May 10.

Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, 3-8-31, Ariake, Koto-ku, Tokyo, 135-8550, Japan. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S0006291X183108
Publisher Site
http://dx.doi.org/10.1016/j.bbrc.2018.05.031DOI Listing
June 2018
13 Reads
2.300 Impact Factor

Drug resistance in anaplastic lymphoma kinase-rearranged lung cancer.

Authors:
Ryohei Katayama

Cancer Sci 2018 Mar 15;109(3):572-580. Epub 2018 Feb 15.

Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, Tokyo, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/cas.13504DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5834792PMC
March 2018
2 Reads
1 Citation

High ratio of T790M to EGFR activating mutations correlate with the osimertinib response in non-small-cell lung cancer.

Lung Cancer 2018 03 4;117:1-6. Epub 2018 Jan 4.

Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, 3-8-31, Ariake, Koto-ku, Tokyo, 135-8550, Japan. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2017.12.018DOI Listing
March 2018
32 Reads
3.960 Impact Factor

Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.

N Engl J Med 2016 Jan 23;374(1):54-61. Epub 2015 Dec 23.

Massachusetts General Hospital Cancer Center (A.T.S., L.F., J.F.G., L.D., R.L.F., K.R.S., J.L., G.G., J.A.E.) and the Department of Pathology (A.J.I., L.L., G.G.), Massachusetts General Hospital, Boston, and the Broad Institute of the Massachusetts Institute of Technology and Harvard, Cambridge (I.L., G.G.) - all in Massachusetts; Pfizer Worldwide Research and Development, La Jolla, CA (S.B., A.B., B.J.B., Y.-L.D., W.L., L.P.J., T.S., S.T., M.M., T.W.J.); and the Japanese Foundation for Cancer Research, Tokyo (R.K.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1508887DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4773904PMC
January 2016
66 Reads
89 Citations
55.873 Impact Factor

Therapeutic targeting of anaplastic lymphoma kinase in lung cancer: a paradigm for precision cancer medicine.

Clin Cancer Res 2015 May;21(10):2227-35

Massachusetts General Hospital Cancer Center, Boston, Massachusetts. Department of Medicine, Harvard Medical School, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-14-2791DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4435823PMC
May 2015
35 Reads
8.722 Impact Factor

RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer.

Nat Commun 2015 Mar 11;6:6377. Epub 2015 Mar 11.

1] Massachusetts General Hospital Cancer Center, Massachusetts General Hospital, 55 Fruit Street, Boston, Massachusetts 02114, USA [2] Department of Medicine, Harvard Medical School, 25 Shattuck Street, Boston, Massachusetts 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/ncomms7377DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4357281PMC
March 2015
99 Reads
10.742 Impact Factor

Cabozantinib overcomes crizotinib resistance in ROS1 fusion-positive cancer.

Clin Cancer Res 2015 Jan 28;21(1):166-74. Epub 2014 Oct 28.

Division of Experimental Chemotherapy, Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, Tokyo, Japan. Department of Medical Genome Science, Graduate School of Frontier Science, The University of Tokyo, Tokyo, Japan.

View Article

Download full-text PDF

Source
http://clincancerres.aacrjournals.org/content/early/2014/12/
Web Search
http://clincancerres.aacrjournals.org/cgi/doi/10.1158/1078-0
Publisher Site
http://dx.doi.org/10.1158/1078-0432.CCR-14-1385DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4286456PMC
January 2015
135 Reads
8.722 Impact Factor

Tivantinib (ARQ 197) exhibits antitumor activity by directly interacting with tubulin and overcomes ABC transporter-mediated drug resistance.

Mol Cancer Ther 2014 Dec 13;13(12):2978-90. Epub 2014 Oct 13.

The Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, Tokyo, Japan. Department of Medical Genome Sciences, Graduate School of Frontier Sciences, The University of Tokyo, Tokyo, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1535-7163.MCT-14-0462DOI Listing
December 2014
52 Reads
5.683 Impact Factor

Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib.

Clin Cancer Res 2014 Nov 16;20(22):5686-96. Epub 2014 Sep 16.

Massachusetts General Hospital Cancer Center, Charlestown, Massachusetts. Department of Medicine, Harvard Medical School, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-14-1511DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4233168PMC
November 2014
55 Reads
8.722 Impact Factor

Cytotoxic activity of tivantinib (ARQ 197) is not due solely to c-MET inhibition.

Cancer Res 2013 May 18;73(10):3087-96. Epub 2013 Apr 18.

Massachusetts General Hospital Cancer Center, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-12-3256DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3759033PMC
May 2013
36 Reads
9.330 Impact Factor

AP-1-Dependent miR-21 expression contributes to chemoresistance in cancer stem cell-like SP cells.

Oncol Res 2010 ;19(1):23-33

Division of Experimental Chemotherapy, Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, Tokyo, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3727/096504010x12828372551759DOI Listing
January 2011
6 Reads
0.920 Impact Factor

Cell-permeable carboxyl-terminal p27(Kip1) peptide exhibits anti-tumor activity by inhibiting Pim-1 kinase.

J Biol Chem 2011 Jan 9;286(4):2681-8. Epub 2010 Nov 9.

Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, Tokyo 135-8550, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1074/jbc.M109.092452DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3024764PMC
January 2011
35 Reads
4.573 Impact Factor

Modulation of Wnt signaling by the nuclear localization of cellular FLIP-L.

J Cell Sci 2010 Jan;123(Pt 1):23-8

Institute of Molecular and Cellular Biosciences, The University of Tokyo, Bunkyo-ku, Tokyo 113-0032, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1242/jcs.058602DOI Listing
January 2010
51 Reads
5.432 Impact Factor

Dofequidar fumarate sensitizes cancer stem-like side population cells to chemotherapeutic drugs by inhibiting ABCG2/BCRP-mediated drug export.

Cancer Sci 2009 Nov 17;100(11):2060-8. Epub 2009 Jul 17.

Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, Japanese Foundation for Cancer Research, Tokyo, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1349-7006.2009.01288.xDOI Listing
November 2009
13 Reads

TUSC4/NPRL2, a novel PDK1-interacting protein, inhibits PDK1 tyrosine phosphorylation and its downstream signaling.

Cancer Sci 2008 Sep 4;99(9):1827-34. Epub 2008 Jul 4.

Division of Experimental Chemotherapy, Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, 3-10-6 Ariake, Koto-ku, Tokyo 135-8550, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1349-7006.2008.00874.xDOI Listing
September 2008
17 Reads

Pim kinases promote cell cycle progression by phosphorylating and down-regulating p27Kip1 at the transcriptional and posttranscriptional levels.

Cancer Res 2008 Jul;68(13):5076-85

Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, The University of Tokyo, Tokyo, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-08-0634DOI Listing
July 2008
26 Reads
9.330 Impact Factor

Impairment of the ubiquitin-proteasome system by cellular FLIP.

Genes Cells 2007 Jun;12(6):735-44

Institute of Molecular and Cellular Biosciences, The University of Tokyo, Bunkyo-ku, Tokyo 113-0032, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1365-2443.2007.01087.xDOI Listing
June 2007
31 Reads
2.810 Impact Factor

Cell differentiation inducers derived from thalidomide.

Bioorg Med Chem Lett 2005 Jul;15(13):3212-5

Institute of Molecular and Cellular Biosciences, The University of Tokyo, 1-1-1 Yayoi, Bunkyo-ku, Tokyo 113-0032, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bmcl.2005.05.005DOI Listing
July 2005
44 Reads
2.420 Impact Factor

Cellular FLIP inhibits beta-catenin ubiquitylation and enhances Wnt signaling.

Mol Cell Biol 2004 Oct;24(19):8418-27

Institute of Molecular and Cellular Biosciences, The University of Tokyo, Yayoi, Bunkyo-ku, Tokyo 113-0032, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1128/MCB.24.19.8418-8427.2004DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC516746PMC
October 2004
23 Reads
4.780 Impact Factor

Apollon ubiquitinates SMAC and caspase-9, and has an essential cytoprotection function.

Nat Cell Biol 2004 Sep 8;6(9):849-60. Epub 2004 Aug 8.

Institute of Molecular and Cellular Biosciences, The University of Tokyo, 1-1-1, Yayoi, Bunkyo-ku, Tokyo 113-0032, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/ncb1159DOI Listing
September 2004
8 Reads
19.680 Impact Factor

Complex N-glycosylated form of nicastrin is stabilized and selectively bound to presenilin fragments.

FEBS Lett 2002 Jun;520(1-3):117-21

Department of Neuropathology and Neuroscience, Graduate School of Pharmaceutical Sciences, University of Tokyo, 7-3-1 Hongo, Bunkyo, Tokyo 113-0033, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/s0014-5793(02)02802-8DOI Listing
June 2002
4 Reads
3.170 Impact Factor

Top co-authors

Naoya Fujita
Naoya Fujita

Institute of Molecular and Cellular Biosciences

17
Jeffrey A Engelman
Jeffrey A Engelman

Massachusetts General Hospital Cancer Center

15
Alice T Shaw
Alice T Shaw

Massachusetts General Hospital Cancer Center

14
Luc Friboulet
Luc Friboulet

California; Cancer Chemotherapy Center and Cancer Institute Hospital

9
Justin F Gainor
Justin F Gainor

Massachusetts General Hospital

9
Takashi Tsuruo
Takashi Tsuruo

Cancer Chemotherapy Center

8
Sumie Koike
Sumie Koike

Cancer Chemotherapy Center

7
Makoto Nishio
Makoto Nishio

Cancer Institute Hospital

6
Elizabeth L Lockerman
Elizabeth L Lockerman

Massachusetts General Hospital Cancer Center

6